A method of treatment of tuberculosis of the urinary system

 

(57) Abstract:

The invention relates to medicine, namely to urology, and pulmonology, and can be used in the treatment of tuberculosis of the urinary system. The essence of the proposed method is to correct the effects of anti-tuberculosis drugs by enhancing their active inclusion in the comprehensive treatment of levorin, furadonin and nitroxoline in doses smaller pharmacopoeial 300 times. The use of the method can improve therapeutic effect, to ensure a complete cure in 60-70% table 5.

The invention relates to medicine, namely to urology.

It is known that substances such as quinacrine, ethacridine, flatrides, furacin, furadonin, chinosol, 5-NOK, chlorpromazine, etaperazin, chlorprothixene in vitro experiments in combination with isoniazid and rifampicin in 2-8 times increased the activity of these anti-TB drugs.

Studying the reasons for late diagnosis of protoparmelia, in some patients was established certain regularity in the timing of detection of tuberculosis in the matter, took medication the patient or not. Among them, the increase in terms of identifying protoparmelia influenced furadonin, levorin, Nita clearly dependent cases among patients, treated in terms of a specialized sanatorium, was more than 10%

However, for clinical application Lavoine, furadonin and nitroxoline has one drawback: it is the impossibility of their long-term use TB patients, as required by the clinic tuberculosis.

Levorin, furadonin and nitroxoline beyond low doses (300 times lower than on their absolute activity) loses its main antibacterial properties to the previously sensitive to them non-specific bacterial flora, but continue to keep trapnest biological impact on tuberculosis microbacteria.

Summing up the preliminary results of the studies to practical use levorin furadonin and nitroxoline in the clinic protoparmelia were established the following relationships: the combined use of medicines gives the summation of effects, so their combined use is preferable; prolonged use of levorin, furadonin, nitroxoline, at a dose of 300 times lower than the daily therapeutic doses does not cause fiziologicheskii patients toxico-allergic complications; the use of these drugs in the treatment of drugs; the increase in anti-TB activity is possible only through joint, permanent and long enough drugs and levorin, furadonin, nitroxoline.

The method was tested in 158 patients aged 30 to 62 years with the previously established active tuberculous process in the urinary system.

For the purposes of a comparative study of the effect of the inclusion of adjuvant or tactivin in the complex therapy with larobina, furadonin, nitroxoline from among the subjects of the experimental group was selected portion fiziologicheskii patients (78 patients) with similar clinical characteristics protoparmelia.

A control group of individuals (78 patients) in its clinical characteristics did not differ from experienced and was also represented by patients with active and widespread tuberculosis.

The distribution of patients in the studied groups were also conducted with regard to the prevalence of renal destruction (common form among persons with destructive forms was 94,18% of cases), pyelonephritis (associated pyelonephritis, caused mainly grammaticalising, quite resistant to antibiotics and chemotherapeutic media is. .

In the study the number of patients with lesions of the urinary tract disturbance of outflow of urine, severe CRF was not. Functional failure of the kidneys mainly corresponded to the latency and offset stages of CRF and was detected mainly in people with only one kidney, which allows for optimal dosages.

The combination of therapeutic agents was determined by the conditions of ongoing research. At the same time used a combination of three drugs on the conventional schemes. Rifampicin was administered at the rate of 10 mg per 1 kg of body weight of the patient, to 0.9 per day, isoniazid 10 mg/kg up to 1 g per day, in combination with ethambutol (20 mg/kg up to 1 g per day) with streptomycin (15 mg/kg up to 1 g per day) or ciprofloxacin (15 mg/kg up to 1 g per day) and protionamide (15 mg/kg up to 1 g per day).

The dose and dosing frequency levorin, furadonin and nitroxoline shown in the table. 2.

The immunomodulators taktivin or adjuvant was used according to the specified schema.

The control treatment was carried out in dynamics using conventional methods and immunological tests, ELISA, RNA-F. as compared with other methods, ELISA, RNA-f was the of Avani were evaluated according to these tests after 2 months. from the beginning of treatment. Methodology and evaluation of the results of ELISA and RNA-f remained the same.

For various reasons, the initial number of patients in the observation groups decreased, but it is qualitatively affected the study results.

Application in complex treatment of protoparmelia protivotuberkuleznykh drugs and levorin, furadonin, nitroxoline contributed to the fact that in 18 (23,68%) patients, PTT was not determined. 40 (52,63%) patients came lower titers of antibody, the remaining 18 (23,65%) patients indicators ELISA, RNA-f remained the same, although subjective patients feel better. Thus, 76,31% of patients, according to immunological tests, there came a marked reduction in the activity of the specific process in the urinary system.

The study of the dynamics of immunological tests ELISA, RNA-f patients, the control group showed that the outcome of TB treatment seem modest, lower titers of PTAT occurred only in 26 (34,66%) patients (see table. 3).

The use of immunomodulators in the treatment of patients with chronic current, active tuberculosis of the kidney was studied in 39 patients.

The use of adjuvant IO process in the urinary system 58,97% of patients.

It is obvious that in the course of specific treatment in combination with the use of levorin, furadonin, nitroxoline and immunomodulators should expect more of the existing changes in the dynamics ELISA, RNA-F.

However, the reduction of the titer of PTAT came only in 80,55% of cases (see tab. 4), which is higher than the experimental group (using levorin, furadonin, nitroxoline) only 4.24% per

A mathematical treatment (table. 4) allowed us to conclude that the combined use of levorin, furadonin and nitroxoline as a method of increasing the effectiveness of specific treatment is justified and its pharmacodynamic interaction is potentiated character.

Therefore, the use of these drugs in the treatment of protoparmelia can be considered as a method of potentionally specific activity of anti-TB drugs.

In the process metropolo the treatment of chronic forms of protoparmelia has been proven a clear dependence of the dynamics of the inflammatory process in the urinary system from the combined use of levorin, furadonin and nitroxoline while reducing their daily therapeutic doses more than 300 times.

The use of immunomodulators: tequilana or adjuvant in treatment of active protoparmelia was less effective in comparison with the appointment of potentiating funds. Combined use potentiodynamic drugs and immunomodulators had significant difference in comparison with the use of potentiating funds.

In the treatment of protoparmelia use levorin, furadonin and nitroxoline can be considered as a method of potentiating the specific activity of anti-TB drugs.

A METHOD of TREATMENT of TUBERCULOSIS of the URINARY SYSTEM, including the introduction of anti-TB drugs, characterized in that it further impose furadonin and nitroxoline 0,001 grams per day and levorin 0,005 grams per day.

 

Same patents:

The invention relates to the production of new proizvodnyh of thiazolidine that are used in pharmaceutical compositions

The invention relates to methods of producing substituted imidazole derivatives and their non-toxic pharmaceutically acceptable acid additive salts

The invention relates to the synthesis of new biologically active chemical compounds, specifically to N-2-(I-R1-5-R2-6-R3-benzimidazolyl)-Succinimidyl acids of General formula I

where (a) R1=n-C4H9, R2=R3=H;

b) R1= CH3, R2= R3=Br, which have neuroleptic, antihypoxic and antiarrhythmic activity, and can find application in medicine

The invention relates to the field of organic chemistry, specifically to an improved method of obtaining 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl] 4H-carbazole-4-or its salts or their hydrates, as well as intermediates for their synthesis, which can find application in pharmaceutical industry

The invention relates to new chemical compounds with valuable pharmacological properties, namely, condensed the five-membered heterocycles of General formula

(1) where R1the atom of hydrogen, fluorine, chlorine or bromine, alkyl-, aralkyl-, aryl-, heteroaryl-, R3O-, (R3)2N-, R4CO - NR3-, alkylsulfonyl - NR3-, arylsulfonyl - NR3-, R3S-, R3SO, R3S2O-, or R5group, and R3is a hydrogen atom, an alkyl group containing from 1 to 6 carbon atoms, aryl, heteroaryl, kalkilya, carboxialkilnuyu or alkoxycarbonylmethyl group;

R4a hydrogen atom, alkyl or CNS group containing 1-6 carbon atoms, aryl, heteroaryl or kalkilya group containing 1-6 carbon atoms in the alkyl part;

R5azetidinone, pyrolidine, hexamethyleneimino or heptamethylnonane or piperidino group in which the methylene group in the fourth position may be substituted with oxygen, sulfenyl, sulfinil or sulfonylureas or aminogroups, which can be substituted for R3, R4CO4, alkylsulfonyl - or aryl is

The invention relates to medicine and can find application in practical medicine as a remedy to relieve alcohol withdrawal

The invention relates to the field of medicine and relates to medicinal products for parenteral administration

FIELD: medicine, oncology.

SUBSTANCE: the present innovation deals with treating patients with uterine cervix cancer with relapses in parametral fiber and in case of no possibility for radical operative interference and effect of previous radiation therapy. During the 1st d of therapy one should intravenously inject 30 mg platidiam incubated for 1 h at 37 C with 150 ml autoblood, during the next 3 d comes external irradiation per 2.6 G-r. During the 5th d of therapy one should introduce the following composition into presacral space: 60 ml 0.5%-novocaine solution, 1 ml hydrocortisone suspension, 2 ml 50%-analgin solution, 1 ml 0.01%-vitamin B12 solution, 1.6 g gentamycine, 800 mg cyclophosphan, 10 mg metothrexate. These curative impacts should be repeated at mentioned sequence four times. The method enables to decrease radiation loading and toxic manifestations of anti-tumor therapy at achieving increased percent of tumor regression.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: medicine, cardiology.

SUBSTANCE: the suggested method should be performed at the background of medicinal therapy with preparations out of statins group, tevetene, polyoxidonium and conducting seances of plasmapheresis by removing 800 ml plasma twice weekly with N 5 due to additional intramuscular injection of immunophan 0.005%-1.0 with N 10 and fluimucyl 300 mg intravenously daily with N 5-10, total course of therapy lasts for 2 mo. The method provides modulation of leukocytic functional activity, moreover, due to altered cytokine profile and, thus, through disintegration of protein-lipid complexes participating in the development of atherosclerotic platelets.

EFFECT: higher efficiency of therapy.

3 ex

FIELD: medicine, endocrinology, pharmacology, pharmacy.

SUBSTANCE: invention relates to a pharmaceutical combined composition used for treatment or prophylaxis of hypertension in patients suffering with diabetes mellitus. The composition comprises AT1-antagonist valsartan or its pharmaceutically acceptable salt and calcium channel blocking agent or its pharmaceutically acceptable salt, and pharmaceutically acceptable carrier. The composition elicits synergistic effect and expanded spectrum effect.

EFFECT: improved and valuable medicinal properties of composition.

10 cl, 3 tbl

FIELD: organic chemistry, pharmacy.

SUBSTANCE: invention relates to new derivatives of benzimidazole represented by the following formula (I) or its salt:

wherein R1 represents (lower)-alkyl group; R2 represents aromatic (lower)-alkyl group that can be substituted with one or more groups taken among halogen atom, alkyl group, halogen-(lower)-alkyl group, nitro-group, aromatic group, aromatic (lower)-alkoxy-group, (lower)-cycloalkyloxy-(lower)-alkyl group, aromatic (lower)-alkyl group, aromatic (lower)-alkenyl group, aromatic (lower)-alkynyl group, aromatic oxy-(lower)-alkyl group, (lower)-cycloalkyl-(lower)-alkoxy-group, alkenyl group, (lower)-alkoxy-group, (lower)-alkylthio-group and (lower)-alkanesulfonylcarbamoyl group; R3 represents alkyl group, hydroxy-(lower)-alkyl group, alkenyl group, aromatic group, halogenated aromatic group, (lower)-alkyl aromatic group, (lower)-alkenyl aromatic group or aromatic (lower)-alkenyl group; -X- represents cross-linking group represented by one of the following formulas: (II) , (III) , (IV) , (V) . Also, invention relates to pharmaceutical compositions eliciting activity that reduces blood glucose level based on this compound. Invention provides preparing new compounds and pharmaceutical compositions based on thereof used for prophylaxis and treatment of damaged tolerance to glucose, diabetes mellitus, insulin-resistance syndrome, vascular failures syndrome, hyperlipidemia and cardiovascular disorders.

EFFECT: valuable medicinal properties of compounds and compositions.

16 cl, 1 tbl, 86 ex

FIELD: medicine, pharmacology, pharmacy.

SUBSTANCE: invention proposes the composition comprising xenon as NMDA-antagonist and alpha-2-adrenergic agonist used for treatment of tetanus or narcotics (alcohol) withdrawal syndrome, states with chronic pain syndrome. Also, invention relates to the anesthetic composition comprising xenon and alpha-2-adrenergic agonist and to a method for anesthesia. The synergistic interaction of xenon as NMDA-antagonist and alpha-2-adrenergic agonist provides reducing the dose and to maintain the prolonged effectiveness by prevention for arising the drug habitation to the claimed preparation.

EFFECT: valuable medicinal properties of composition.

9 cl, 6 dwg, 6 ex

FIELD: pharmaceutics.

SUBSTANCE: the present innovation deals with mixing water for injections, conservation agent, metronidasol till complete dissolving at 50-60 C, adding a buffer (NaOH solution) pH 4.5-6.5 at pre-estimated quantity of water, then one should sterilize the obtained medicinal form due to membranous filtration followed by sterile packaging. As a conservation agent one should apply sodium chloride at the quantity of 1.5-2.0 against metronidasol weight, then metronidasol solution should be supplemented with a half-volume of sodium chloride solution, after complete dissolving the obtained solution should be supplemented with the rest quantity of sodium chloride solution. As for membranous filtration it should be carried out by applying a capsule out of polypropylene with hydrophilic membrane of 1.2 mcm. The method provides no crystallization of an active substance during prolonged period of time.

EFFECT: higher therapeutic efficiency.

1 ex, 1 tbl

FIELD: medicine, cardiology.

SUBSTANCE: it is suggested to apply cortisol antagonists in addition to clonidine while manufacturing preparation to treat heart failure. Moreover, one should introduce cortisol antagonist or a product that includes cortisol antagonist along with the second medicinal preparation being a combined preparation to be applied either simultaneously, separately or successively. The present innovation provides decreased symptoms of heart failure at decreasing cardiac muscle's fibrosis and heart sizes due to preferable impact upon glucocorticoid receptors in patient's heart and/or kidneys.

EFFECT: higher efficiency of application.

12 cl, 2 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to a group of new derivatives of 4,5-dihydro-1H-pyrazole of the general formula (I):

wherein R means phenyl, thienyl or pyridyl and these indicated groups can be substituted with (C1-C3)-alkoxy-group or halogen atom; R1 means phenyl that can be substituted with (C1-C3)-alkoxy-group or pyridyl group; R2 means hydrogen atom or hydroxy-group; Aa means one group among the following groups: (i) , (ii) , (iii) , (iv) or (v) ; R4 and R5 mean independently from one another hydrogen atom or (C1-C8)-branched or unbranched alkyl; or R4 means acetamido- or dimethylamino-group or 2,2,2-trifluoroethyl, or phenyl, or pyridyl under condition that R5 means hydrogen atom; R6 means hydrogen atom at (C1-C3)-unbranched alkyl; Bb means sulfonyl or carbonyl; R3 means benzyl, phenyl or pyridyl that can be substituted with 1, 2 or 3 substitutes Y that can be similar or different and taken among the group including (C1-C3)-alkyl or (C1-C3)-alkoxy-group, halogen atom, trifluoromethyl; or R3 means naphthyl, and its racemates, mixtures of diastereomers and individual stereoisomers and as well as E-isomers, Z-isomers and mixture of E/Z-compounds of the formula (I) wherein A has values (i) or (ii), and its salt. These compounds are power antagonists of Cannbis-1 (CB1) receptor and can be used for treatment of psychiatric and neurological diseases. Except for, invention relates to a pharmaceutical composition used for treatment of some diseases mediated by CB1-receptor, to a method for preparing this composition, a method for preparing representatives of compounds of the formula (I) wherein Aa means group of the formulae (i) or (ii), intermediate compounds used for preparing compounds of the formula (I) and to a method for treatment of some diseases mediated by CB1-receptor.

EFFECT: valuable medicinal properties of compounds.

16 cl, 9 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to a group of new derivatives of 4,5-dihydro-1H-pyrazole of the general formula (I):

wherein R means phenyl, thienyl or pyridyl and these indicated groups can be substituted with (C1-C3)-alkoxy-group or halogen atom; R1 means phenyl that can be substituted with (C1-C3)-alkoxy-group or pyridyl group; R2 means hydrogen atom or hydroxy-group; Aa means one group among the following groups: (i) , (ii) , (iii) , (iv) or (v) ; R4 and R5 mean independently from one another hydrogen atom or (C1-C8)-branched or unbranched alkyl; or R4 means acetamido- or dimethylamino-group or 2,2,2-trifluoroethyl, or phenyl, or pyridyl under condition that R5 means hydrogen atom; R6 means hydrogen atom at (C1-C3)-unbranched alkyl; Bb means sulfonyl or carbonyl; R3 means benzyl, phenyl or pyridyl that can be substituted with 1, 2 or 3 substitutes Y that can be similar or different and taken among the group including (C1-C3)-alkyl or (C1-C3)-alkoxy-group, halogen atom, trifluoromethyl; or R3 means naphthyl, and its racemates, mixtures of diastereomers and individual stereoisomers and as well as E-isomers, Z-isomers and mixture of E/Z-compounds of the formula (I) wherein A has values (i) or (ii), and its salt. These compounds are power antagonists of Cannbis-1 (CB1) receptor and can be used for treatment of psychiatric and neurological diseases. Except for, invention relates to a pharmaceutical composition used for treatment of some diseases mediated by CB1-receptor, to a method for preparing this composition, a method for preparing representatives of compounds of the formula (I) wherein Aa means group of the formulae (i) or (ii), intermediate compounds used for preparing compounds of the formula (I) and to a method for treatment of some diseases mediated by CB1-receptor.

EFFECT: valuable medicinal properties of compounds.

16 cl, 9 ex

FIELD: organic chemistry, chemical technology, pharmacy.

SUBSTANCE: invention relates to new spiroimidazolidine derivatives of the formula (1):

wherein R1 represents hydrogen atom or methyl; R2 represents phenyl or (C1-C4)-alkyl; X represents -CH2-CH2- or -CH2-CH2-CH2-; W represents isopropyl or cyclopropyl; V represents hydrogen atom or methoxy-group; E represents -CO-R3 wherein R3 represents hydroxy-group, (C1-C4)-alkoxy- or amino-group; phenyl represents unsubstituted phenyl residue or phenyl residue substituted with one or some similar or different substitutes taken among the group consisting of (C1-C4)-alkoxy-, methylenedioxy- and ethylenedioxy-group in all its stereoisomeric forms and their mixtures in all ratios, and to its physiologically acceptablesalts. Also, invention relates to a method for preparing compounds of the formula (1) and pharmaceutical composition based on these compounds. Invention provides preparing new compounds eliciting the inhibitory effect with respect o leukocytes adhesion.

EFFECT: improved preparing method, valuable medicinal properties of compounds.

16 cl, 1 tbl, 41 ex

Up!